For the year ending November 30, 2024, New Sharp Pharmaceuticals filed a monthly statement on the movement of its share capital and shares. The report showed that the company's regulated/registered share capital remained at HK$3 billion with a face value of HK$0.05 per share for a total of HK$0.15 billion, unchanged from the previous month.In terms of issued shares, the number of ordinary shares remained at 1.671 billion shares and the number of shares in stock was 0, indicating no shares added or decreased during the month. In the share option plan adopted by the company in 2013, the number of share options remained unchanged at 0.1282 billion shares.Under the Listing Rules of the HKEx, Novicut Pharmaceuticals confirms that the handling of all securities issues and inventory shares has been authorised by the Board of Directors and in compliance with relevant legal and regulatory requirements.

For the year ending November 30, 2024, New Sharp Pharmaceuticals filed a monthly statement on the movement of its share capital and shares. The report showed that the company's regulated/registered share capital remained at HK$3 billion with a face value of HK$0.05 per share for a total of HK$0.15 billion, unchanged from the previous month.In terms of issued shares, the number of ordinary shares remained at 1.671 billion shares and the number of shares in stock was 0, indicating no shares added or decreased during the month. In the share option plan adopted by the company in 2013, the number of share options remained unchanged at 0.1282 billion shares.Under the Listing Rules of the HKEx, Novicut Pharmaceuticals confirms that the handling of all securities issues and inventory shares has been authorised by the Board of Directors and in compliance with relevant legal and regulatory requirements.